3.8643
前日終値:
$3.92
開ける:
$3.92
24時間の取引高:
514.54K
Relative Volume:
0.18
時価総額:
$636.23M
収益:
$296.15M
当期純損益:
$24.02M
株価収益率:
32.04
EPS:
0.1206
ネットキャッシュフロー:
$127.01M
1週間 パフォーマンス:
+6.13%
1か月 パフォーマンス:
-0.89%
6か月 パフォーマンス:
+0.91%
1年 パフォーマンス:
+587.80%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
名前
Ironwood Pharmaceuticals Inc
セクター
電話
617-621-7722
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
IRWD
Ironwood Pharmaceuticals Inc
|
3.865 | 645.28M | 296.15M | 24.02M | 127.01M | 0.1206 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.92 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.295 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
80.37 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
568.01 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | ダウングレード | Jefferies | Buy → Hold |
| 2025-04-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 開始されました | Leerink Partners | Market Perform |
| 2024-08-08 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 開始されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Wells Fargo | Overweight |
| 2023-11-09 | 開始されました | Jefferies | Buy |
| 2023-09-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-02 | 開始されました | CapitalOne | Overweight |
| 2022-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-09-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 開始されました | Northland Capital | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | アップグレード | JP Morgan | Underweight → Neutral |
| 2018-11-07 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 開始されました | H.C. Wainwright | Sell |
| 2018-05-09 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2017-07-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 開始されました | Wells Fargo | Outperform |
| 2017-04-07 | 繰り返されました | Mizuho | Buy |
| 2017-02-22 | 繰り返されました | Barclays | Equal Weight |
| 2016-11-04 | 繰り返されました | Mizuho | Buy |
| 2016-10-24 | 繰り返されました | Wedbush | Neutral |
| 2016-10-10 | 繰り返されました | Mizuho | Buy |
| 2016-09-27 | 繰り返されました | WallachBeth | Hold |
すべてを表示
Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant - Stock Titan
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement? - Insider Monkey
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Top Small-Cap Stocks to Watch: Ironwood Pharmaceuticals (IRWD) L - GuruFocus
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharma drops after CFO transition - MSN
Ironwood Pharmaceuticals: Still A Profitable Opportunity (NASDAQ:IRWD) - Seeking Alpha
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A - Stock Titan
Ironwood Pharmaceuticals, Inc.Class A Common Stock (NQ: IRWD - FinancialContent
Renaissance reports 4.90% stake in Ironwood (IRWD) - Stock Titan
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharma Announces CFO Resignation and Interim Successor - The Globe and Mail
Ironwood stock down despite Q1 earnings and revenue beat - MSN
Earnings call transcript: Ironwood’s Q1 2026 earnings beat forecasts, stock dips - Investing.com
Ironwood Pharmaceuticals: CFO Resignation Knocks SharesA Downgrade Is Due (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) Shares Drop 12% After CFO Resignation Announcement - GuruFocus
Ironwood Pharma stock drops after CFO exit (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details and Regulatory Disclosures - Minichart
Ironwood Pharmaceuticals IncGregory Martini resigns as CFO effective May 15, 2026SEC filing - marketscreener.com
[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event - Stock Titan
TradingKey - TradingKey
Ironwood Pharmaceuticals stock (US46333X1081): Revenue surge and earnings beat signal turnaround - AD HOC NEWS
Ironwood Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-05-11 - Seeking Alpha
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: Ironwood Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat - sharewise.com
Ironwood Pharmaceuticals Q1 Earnings Call Highlights - sharewise.com
Q1 2026 Ironwood Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ironwood: Q1 Earnings Snapshot - theheraldreview.com
Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) 財務データ
収益
当期純利益
現金流量
EPS
Ironwood Pharmaceuticals Inc (IRWD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
大文字化:
|
ボリューム (24 時間):